SC
SNDX icon

Stempoint Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Stempoint Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,215,743
Closed -$28.4M – 106
2026
Q1 		$28.4M Sell
1,215,743
-123,636
-9% -$2.69M 5.44% 3
2025
Q4 		$28.1M Sell
1,339,379
-26,826
-2% -$468K 4.83% 4
2025
Q3 		$21M Sell
1,366,205
-1,006,429
-42% -$13.2M 4.21% 6
2025
Q2 		$22.2M Buy
2,372,634
+774,040
+48% +$8.52M 7.13% 1
2025
Q1 		$19.6M Sell
1,598,594
-1,274,007
-44% -$18M 6.26% 2
2024
Q4 		$38M Buy
2,872,601
+1,141,410
+66% +$19.5M 9.48% 1
2024
Q3 		$33.3M Buy
1,731,191
+319,015
+23% +$6.59M 9.98% 1
2024
Q2 		$29M Buy
1,412,176
+311,188
+28% +$6.51M 8.52% 1
2024
Q1 		$26.2M Buy
1,100,988
+6,494
+0.6% +$145K 6.93% 3
2023
Q4 		$23.7M Buy
+1,094,494
New +$16.8M 6.31% 2

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Stempoint Capital's SNDX Position: Q2 2026 in Review

Stempoint Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 1,215,743 shares — an estimated $28.4M sold.

Stempoint Capital first reported a position in SNDX in Q4 2023 and held it in 10 quarters. The position peaked at $38M in Q4 2024. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Stempoint Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 1,215,743 Syndax Pharmaceuticals shares in Q2 2026, an estimated $28.4M.
  • Stempoint Capital first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Stempoint Capital's Syndax Pharmaceuticals position peaked at $38M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.